Search research articles
Contact Us
Filters
Showing results (121-130 of 169) with videos related to
Page
of 17
Sort By:
Blood
|
July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Judith Trotman, Stephen Opat, David Gottlieb, et al.
Blood Advances
|
February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Cell Reports
|
January 11, 2018
The RNA Polymerase II Factor RPAP1 Is Critical for Mediator-Driven Transcription and Cell Identity
Cian J Lynch, Raquel Bernad, Isabel Calvo, et al.
Nature Medicine
|
March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Cancer Reports (Hoboken, N.J.)
|
July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo, Armando Santoro, Guillaume Cartron, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
Javier Munoz, Allison Rosenthal, Andrew Ip, et al.
American Journal of Hematology
|
August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
Kai Rejeski, Yucai Wang, Omar Albanyan, et al.
Blood
|
February 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
Julio C Chavez, Michael Dickinson, Javier Munoz, et al.
American Journal of Hematology
|
November 26, 2024
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström Macroglobulinemia
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
International Journal of Hematology
|
November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 169) with videos related to
Sort By:
Page
of 17
Blood
|
July 23, 2020
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up
Judith Trotman, Stephen Opat, David Gottlieb, et al.
Blood Advances
|
February 5, 2024
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7
Armin Ghobadi, Javier Munoz, Jason R Westin, et al.
Cell Reports
|
January 11, 2018
The RNA Polymerase II Factor RPAP1 Is Critical for Mediator-Driven Transcription and Cell Identity
Cian J Lynch, Raquel Bernad, Isabel Calvo, et al.
Nature Medicine
|
March 22, 2022
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S Neelapu, Michael Dickinson, Javier Munoz, et al.
Cancer Reports (Hoboken, N.J.)
|
July 19, 2022
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial
Carla Casulo, Armando Santoro, Guillaume Cartron, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 8, 2025
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
Javier Munoz, Allison Rosenthal, Andrew Ip, et al.
American Journal of Hematology
|
August 16, 2023
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
Kai Rejeski, Yucai Wang, Omar Albanyan, et al.
Blood
|
February 12, 2025
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
Julio C Chavez, Michael Dickinson, Javier Munoz, et al.
American Journal of Hematology
|
November 26, 2024
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström Macroglobulinemia
Eric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
International Journal of Hematology
|
November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Page
of 17